CELG - Celgene Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
121.33
-14.63 (-10.76%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close135.96
Open124.50
Bid121.50 x 400
Ask121.64 x 600
Day's Range120.80 - 124.54
52 Week Range96.93 - 147.17
Volume27,765,072
Avg. Volume4,097,239
Market Cap94.92B
Beta1.48
PE Ratio (TTM)37.58
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatch9 hours ago

    Celgene dives 10% after ditching key drug

    The once high-profile drug was expected to bring in as much as $2.4 billion in peak revenue.

  • Motley Fool9 hours ago

    3 Healthcare Stocks for Your Radar

    Why you might want to check out Novocure, Foundation Medicine, and Celgene sooner rather than later.

  • Should You Avoid Celgene Stock After Its Big Pipeline Setback?
    Motley Fool13 hours ago

    Should You Avoid Celgene Stock After Its Big Pipeline Setback?

    The market is reacting like Celgene's future hinged on failed Crohn's disease drug GED-0301. It doesn't.

  • Market Realist2 days ago

    Celgene Stock: Performance in 3Q17

    Celgene stock has risen ~12.3% in 3Q17. It has risen ~17.5% year-to-date as of October 20, 2017.

  • Celgene Down on Discontinued Crohn's Disease Drug Study
    Zacks2 days ago

    Celgene Down on Discontinued Crohn's Disease Drug Study

    Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.

  • Celgene Abandons Crohn's Drug; Could Others Take Its Spot?
    Investor's Business Daily2 days ago

    Celgene Abandons Crohn's Drug; Could Others Take Its Spot?

    Celgene toppled to a four-month low Friday after it scrapped trials in Crohn's disease after a late-stage failure.

  • What Happened in the Stock Market Today
    Motley Fool2 days ago

    What Happened in the Stock Market Today

    On another record day for the major benchmarks, shares of Skechers skyrocketed on earnings and Celgene tumbled after discontinuing a drug trial.

  • Barrons.com2 days ago

    The Biggest Loser: Does Celgene Need to Pipe Up?

    Shares of Celgene (CELG) plunged to the bottom of the S&P 500 today after the drug maker abandoned clinical trials testing its experimental drug Mongersen as a treatment for Crohn’s disease. The stock fell almost 10.8% to close at $121.33 on a day when the S&P 500 posted a 0.5% gain, making Celgene the worst-performing stock in the index. Mongersen was a high-profile drug in Celgene’s pipeline.

  • Associated Press2 days ago

    PayPal and Skechers jump while Celgene tumbles

    Stocks that moved substantially or traded heavily Friday: Celgene Corp., down $14.63 to $121.33 The drugmaker ended late-stage testing of a potential treatment for Crohn's disease. General Electric Co., ...

  • Reuters2 days ago

    GLOBAL MARKETS-U.S. tax plan hopes lift stocks, dollar strengthens

    World stocks advanced, bond yields rose and the U.S. dollar strengthened on Friday on increased hopes President Donald Trump could make progress on his fiscal plans after the U.S. Senate approved a budget blueprint that paves the way for tax cuts. U.S. Republican Senator Rand Paul appeared to back the administration's sweeping tax cut plan, saying he was "all in" for massive tax cuts, even as the Senate passed a key budget measure without his support one day earlier.

  • TheStreet.com2 days ago

    Tax Cut Progress Gives Wall Street Enough Fuel to End With More Records

    Congress makes progress toward tax reform and Wall Street cheers. All major indexes secure new records heading into the weekend.

  • TheStreet.com2 days ago

    Tax Progress Boosts Wall Street, Major Indexes Trade Above Records

    Stocks are rising after the Senate votes for a budget blueprint that paves the way for major tax cuts.

  • How Big of a Deal Is Celgene's Flop?
    Motley Fool2 days ago

    How Big of a Deal Is Celgene's Flop?

    A disappointing late-stage trial failure is causing shares to tumble, but there's a lot going on at this company that could pan out for investors.

  • Barrons.com2 days ago

    Biotech Earnings: Good News on the Way

    BMO Capital Markets’ M. Ian Somaiya takes a look at the biotech sector on Friday, writing that another strong quarter could help the stocks keep climbing. Somaiya writes that he expects solid results from ...

  • Why Celgene Corporation Dropped Today
    Motley Fool2 days ago

    Why Celgene Corporation Dropped Today

    A phase 3 failure sent shares down.

  • Celgene's Whiff Isn't the End of the World
    Bloomberg2 days ago

    Celgene's Whiff Isn't the End of the World

    The drugmaker has a full pipeline, so investors should expect some misses.

  • Investopedia2 days ago

    Celgene's Sharp Sell-Off Is Likely Overdone

    Celgene's stock tanked after it terminated a clinical trial for its ulcerative colitis drug GED-0301.

  • TheStreet.com2 days ago

    Modest Gains Drive Wall Street to Trade at Records as Tax Progress Buoys Spirits

    Stocks are rising after the Senate votes for a budget blueprint that paves the way for major tax cuts.

  • Barrons.com2 days ago

    Celgene: No Surprise? Its 10% Drop Says Different.

    Celgene’s (CELG) efforts to reduce its dependence on the blood cancer drug Revlimid suffered a setback today when the drug maker Celgene said it would abandon testing mongersen, a big treatment for Crohn’s disease. The drug maker announced that it would stop two trials, and would not initiate a third study following a risk-benefit analysis by a data monitoring committee. Celgene says there were “no meaningful safety imbalances” identified in the committee’s analysis.

  • Reuters2 days ago

    US STOCKS-Bank, tech stocks lift Wall Street

    U.S. stocks inched higher on Friday as bank stocks rose and tech stocks recovered, with investor optimism back as Trump administration cleared a hurdle to lower taxes. Bank of America's 2 percent gain was the biggest boost to the S&P. Apple led the gains in the technology index as it rose 0.60 percent after falling 2.5 percent on Thursday.

  • Stocks Open Higher As Skechers, Atlassian, PayPal Soar; GE Slides
    Investor's Business Daily2 days ago

    Stocks Open Higher As Skechers, Atlassian, PayPal Soar; GE Slides

    Stocks jumped at the starting bell Friday, as global markets rebounded and earnings news rolled in.

  • TheStreet.com2 days ago

    Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

    The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.

  • Reuters3 days ago

    US STOCKS-Wall St set to open higher fueled by tax-cut optimism

    Wall Street was poised to open higher on Friday on growth optimism as the Trump administration inched a step closer to implementing its tax-cut plan. Hopes of tax cuts have helped the market rally, as companies expect the move to lift economic growth and inflation. "The good thing is we're seeing incremental positives as we move toward tax cuts," said Art Hogan, chief market strategist at Wunderlich Securities in New York.

  • Here are 4 home run stocks to kick off the World Series: ...
    CNBC Videos2 days ago

    Here are 4 home run stocks to kick off the World Series: ...

    The “Fast Money” traders share their final trades for the day including Harsco Corp, Celgene, Walmart, and Alibaba.

  • Stocks close near session highs
    CNBC Videos2 days ago

    Stocks close near session highs

    Discussing the winners and losers of the market at the closing bell with CNBC Contributor Evan Newmark and Cathie Wood of ARK Invest.